inclusion criteria: 1. age range from 18 to 80 (including 18 and 80 years old), male or female 2. the subject tested positive for sars-cov-2 by nucleic acid test within 96 hours (4 days) prior to initial administration 3. the patient is confirmed to be infected with the covid-19, meeting the diagnostic criteria for mild or moderate patients in the latest version of the covid-19 pneumonia diagnosis and treatment protocol (trial 10th edition) issued by the chinese health commission, and has at least one symptom of sars-cov-2, such as fever, cough, shortness of breath, sore throat, diarrhea, vomiting and taste disturbance within 96 hours before the first administration of the drug 4. according to the 12 common symptom assessment forms of sars-cov-2 infection, the total symptom assessment score of the subjects before randomization was ≥ 2 points 5. there is at least one possible risk factor for severe/critical sars-cov-2: ① age \> 60 years old; (2) patients with cardiovascular and cerebrovascular diseases (including hypertension), diabetes, chronic pulmonary diseases (chronic obstructive pulmonary disease, moderate to severe asthma), chronic liver and kidney diseases, tumors and other underlying diseases, and the disease should be in a stable period; (3) immune dysfunction (such as aids patients, long-term use of corticosteroids or other immunosuppressive drugs to cause immune dysfunction); ④ obesity (body mass index ≥30); ⑤ heavy smokers; ⑥ those who have not received sars-cov-2 vaccine 6. agree to take highly effective contraceptive measures within 3 months after taking the experimental drug 7. the subject can communicate well with the researcher, understand and comply with the requirements of the study, and understand and sign the informed consent

inclusion criteria: 1. age range from 18 to 80 (including 18 and 80 years old), male or female 2. the subject tested positive for sars-cov-2 by nucleic acid test within 96 hours (4 days) prior to initial administration 3. the patient is confirmed to be infected with the covid-19, meeting the diagnostic criteria for mild or moderate patients in the latest version of the covid-19 pneumonia diagnosis and treatment protocol (trial 10th edition) issued by the chinese health commission, and has at least one symptom of sars-cov-2, such as fever, cough, shortness of breath, sore throat, diarrhea, vomiting and taste disturbance within 96 hours before the first administration of the drug 4. according to the 12 common symptom assessment forms of sars-cov-2 infection, the total symptom assessment score of the subjects before randomization was ≥ 2 points 5. there is at least one possible risk factor for severe/critical sars-cov-2: ① age \> 60 years old; (2) patients with cardiovascular and cerebrovascular diseases (including hypertension), diabetes, chronic pulmonary diseases (chronic obstructive pulmonary disease, moderate to severe asthma), chronic liver and kidney diseases, tumors and other underlying diseases, and the disease should be in a stable period; (3) immune dysfunction (such as aids patients, long-term use of corticosteroids or other immunosuppressive drugs to cause immune dysfunction); ④ obesity (body mass index ≥30); ⑤ heavy smokers; ⑥ those who have not received sars-cov-2 vaccine 6. agree to take highly effective contraceptive measures within 3 months after taking the experimental drug 7. the subject can communicate well with the researcher, understand and comply with the requirements of the study, and understand and sign the informed consent

inclusion criteria: age range from 18 to 80 (including 18 and 80 years old), male or female the subject tested positive for sars-cov-2 by nucleic acid test within 96 hours (4 days) prior to initial administration the patient is confirmed to be infected with the covid-19, meeting the diagnostic criteria for mild or moderate patients in the latest version of the covid-19 pneumonia diagnosis and treatment protocol (trial 10th edition) issued by the chinese health commission, and has at least one symptom of sars-cov-2, such as fever, cough, shortness of breath, sore throat, diarrhea, vomiting and taste disturbance within 96 hours before the first administration of the drug according to the 12 common symptom assessment forms of sars-cov-2 infection, the total symptom assessment score of the subjects before randomization was ≥ 2 points there is at least one possible risk factor for severe/critical sars-cov-2: ① age > 60 years old; (2) patients with cardiovascular and cerebrovascular diseases (including hypertension), diabetes, chronic pulmonary diseases (chronic obstructive pulmonary disease, moderate to severe asthma), chronic liver and kidney diseases, tumors and other underlying diseases, and the disease should be in a stable period; (3) immune dysfunction (such as aids patients, long-term use of corticosteroids or other immunosuppressive drugs to cause immune dysfunction); ④ obesity (body mass index ≥30); ⑤ heavy smokers; ⑥ those who have not received sars-cov-2 vaccine agree to take highly effective contraceptive measures within 3 months after taking the experimental drug the subject can communicate well with the researcher, understand and comply with the requirements of the study, and understand and sign the informed consent

inclusion criteria: age range from 18 to 80 (including 18 and 80 years old), male or female the subject tested positive for sars-cov-2 by nucleic acid test within 96 hours (4 days) prior to initial administration the patient is confirmed to be infected with the covid-19, meeting the diagnostic criteria for mild or moderate patients in the latest version of the covid-19 pneumonia diagnosis and treatment protocol (trial 10th edition) issued by the chinese health commission, and has at least one symptom of sars-cov-2, such as fever, cough, shortness of breath, sore throat, diarrhea, vomiting and taste disturbance within 96 hours before the first administration of the drug according to the 12 common symptom assessment forms of sars-cov-2 infection, the total symptom assessment score of the subjects before randomization was ≥ 2 points there is at least one possible risk factor for severe/critical sars-cov-2: ① age > 60 years old; (2) patients with cardiovascular and cerebrovascular diseases (including hypertension), diabetes, chronic pulmonary diseases (chronic obstructive pulmonary disease, moderate to severe asthma), chronic liver and kidney diseases, tumors and other underlying diseases, and the disease should be in a stable period; (3) immune dysfunction (such as aids patients, long-term use of corticosteroids or other immunosuppressive drugs to cause immune dysfunction); ④ obesity (body mass index ≥30); ⑤ heavy smokers; ⑥ those who have not received sars-cov-2 vaccine agree to take highly effective contraceptive measures within 3 months after taking the experimental drug the subject can communicate well with the researcher, understand and comply with the requirements of the study, and understand and sign the informed consent

inclusion criteria: (1) age range from 18 to 80 (including 18 and 80 years old), male or female (2) the subject tested positive for sars-cov-2 by nucleic acid test within 96 hours (4 days) prior to initial administration (3) the patient is confirmed to be infected with the covid-19, meeting the diagnostic criteria for mild or moderate patients in the latest version of the covid-19 pneumonia diagnosis and treatment protocol (trial 10th edition) issued by the chinese health commission, and has at least one symptom of sars-cov-2, such as fever, cough, shortness of breath, sore throat, diarrhea, vomiting and taste disturbance within 96 hours before the first administration of the drug (4)according to the 12 common symptom assessment forms of sars-cov-2 infection, the total symptom assessment score of the subjects before randomization was ≥ 2 points (5)there is at least one possible risk factor for severe/critical sars-cov-2: ① age > 60 years old; (2) patients with cardiovascular and cerebrovascular diseases (including hypertension), diabetes, chronic pulmonary diseases (chronic obstructive pulmonary disease, moderate to severe asthma), chronic liver and kidney diseases, tumors and other underlying diseases, and the disease should be in a stable period; (3) immune dysfunction (such as aids patients, long-term use of corticosteroids or other immunosuppressive drugs to cause immune dysfunction); ④ obesity (body mass index ≥30); ⑤ heavy smokers; ⑥ those who have not received sars-cov-2 vaccine (6) agree to take highly effective contraceptive measures within 3 months after taking the experimental drug (7) the subject can communicate well with the researcher, understand and comply with the requirements of the study, and understand and sign the informed consent

inclusion criteria: (1) age range from 18 to 80 (including 18 and 80 years old), male or female (2) the subject tested positive for sars-cov-2 by nucleic acid test within 96 hours (4 days) prior to initial administration (3) the patient is confirmed to be infected with the covid-19, meeting the diagnostic criteria for mild or moderate patients in the latest version of the covid-19 pneumonia diagnosis and treatment protocol (trial 10th edition) issued by the chinese health commission, and has at least one symptom of sars-cov-2, such as fever, cough, shortness of breath, sore throat, diarrhea, vomiting and taste disturbance within 96 hours before the first administration of the drug (4)according to the 12 common symptom assessment forms of sars-cov-2 infection, the total symptom assessment score of the subjects before randomization was ≥ 2 points (5)there is at least one possible risk factor for severe/critical sars-cov-2: ① age > 60 years old; (2) patients with cardiovascular and cerebrovascular diseases (including hypertension), diabetes, chronic pulmonary diseases (chronic obstructive pulmonary disease, moderate to severe asthma), chronic liver and kidney diseases, tumors and other underlying diseases, and the disease should be in a stable period; (3) immune dysfunction (such as aids patients, long-term use of corticosteroids or other immunosuppressive drugs to cause immune dysfunction); ④ obesity (body mass index ≥30); ⑤ heavy smokers; ⑥ those who have not received sars-cov-2 vaccine (6) agree to take highly effective contraceptive measures within 3 months after taking the experimental drug (7) the subject can communicate well with the researcher, understand and comply with the requirements of the study, and understand and sign the informed consent